US20080194649A1 - Ophthalmologic Compositions And Use Mode Thereof - Google Patents

Ophthalmologic Compositions And Use Mode Thereof Download PDF

Info

Publication number
US20080194649A1
US20080194649A1 US11/908,161 US90816106A US2008194649A1 US 20080194649 A1 US20080194649 A1 US 20080194649A1 US 90816106 A US90816106 A US 90816106A US 2008194649 A1 US2008194649 A1 US 2008194649A1
Authority
US
United States
Prior art keywords
agent
pharmaceutical composition
parasympatholytic
local anaesthetic
phenylephrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/908,161
Other languages
English (en)
Inventor
Walild Khatib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Thea SAS
Original Assignee
Laboratoires Thea SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Thea SAS filed Critical Laboratoires Thea SAS
Assigned to LABORATOIRES THEA reassignment LABORATOIRES THEA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHATIB, WALID
Publication of US20080194649A1 publication Critical patent/US20080194649A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
US11/908,161 2005-03-09 2006-03-09 Ophthalmologic Compositions And Use Mode Thereof Abandoned US20080194649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0502357A FR2882930B1 (fr) 2005-03-09 2005-03-09 Nouvelles compositions ophtalmologiques et leur mode d'utilisation
FR0502357 2005-03-09
PCT/FR2006/000528 WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000528 A-371-Of-International WO2006095095A1 (fr) 2005-03-09 2006-03-09 Compositions ophtalmologiques et leur mode d’utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/464,524 Division US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Publications (1)

Publication Number Publication Date
US20080194649A1 true US20080194649A1 (en) 2008-08-14

Family

ID=35058756

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/908,161 Abandoned US20080194649A1 (en) 2005-03-09 2006-03-09 Ophthalmologic Compositions And Use Mode Thereof
US13/464,524 Active 2027-05-03 US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/464,524 Active 2027-05-03 US9289399B2 (en) 2005-03-09 2012-05-04 Ophthalmologic compositions and use mode thereof

Country Status (26)

Country Link
US (2) US20080194649A1 (fr)
EP (1) EP1858481B1 (fr)
JP (1) JP2008532985A (fr)
KR (1) KR20070111501A (fr)
CN (1) CN101151018A (fr)
CA (1) CA2598503C (fr)
CY (2) CY1121865T1 (fr)
DK (1) DK1858481T3 (fr)
ES (1) ES2728071T3 (fr)
FR (1) FR2882930B1 (fr)
HR (1) HRP20191044T1 (fr)
HU (1) HUE043668T2 (fr)
IL (1) IL185197A0 (fr)
LT (2) LT1858481T (fr)
LU (1) LUC00136I2 (fr)
MA (1) MA29269B1 (fr)
MX (1) MX2007010295A (fr)
NL (1) NL301017I2 (fr)
NO (2) NO339793B1 (fr)
PL (1) PL1858481T3 (fr)
PT (1) PT1858481T (fr)
RU (1) RU2392925C2 (fr)
SI (1) SI1858481T1 (fr)
TN (1) TNSN07343A1 (fr)
TR (1) TR201908487T4 (fr)
WO (1) WO2006095095A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111029A3 (fr) * 2011-02-18 2012-10-18 M/S. Appasamy Associates Composition ophtalmique pour la dilatation des pupilles
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
US9066856B2 (en) 2012-10-24 2015-06-30 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPA20110004A1 (it) * 2011-02-23 2012-08-24 Francesco Paolo Montalto Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi).
CN103159672A (zh) * 2012-07-16 2013-06-19 湖南尔文生物科技有限公司 一种托品酰胺的制备方法
RU2525512C1 (ru) * 2013-03-28 2014-08-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации
JP2016532723A (ja) * 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法
CN105213418B (zh) * 2015-11-11 2019-01-22 中国人民解放军第四军医大学 一种眼科术前用复方滴眼液及其制备方法
EP3503873A4 (fr) * 2016-08-25 2020-04-15 Harrow IP, LLC Compositions ophtalmiques à base d'épinéphrine pour administration intraoculaire et leurs procédés de production
RU2649534C1 (ru) * 2017-05-10 2018-04-03 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ анестезии при факоэмульсификации катаракты
RU2662423C1 (ru) * 2017-07-26 2018-07-25 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ проведения обезболивания при выполнении витреоретинальных операций

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780760B2 (ja) * 1986-07-28 1995-08-30 ライオン株式会社 安定化されたフエニレフリン系液剤
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US6319240B1 (en) * 1999-05-25 2001-11-20 Iomed, Inc. Methods and apparatus for ocular iontophoresis
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
JP4150846B2 (ja) * 2001-03-28 2008-09-17 参天製薬株式会社 ステロイドを有効成分とする網脈絡膜疾患治療剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026323A (en) * 1960-03-22 1962-03-20 Rubin J Schacter Salts of tribasic acids
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
US20040013729A1 (en) * 2002-07-18 2004-01-22 Buono Lawrence M. Single-drop multiple-agent composition for topical delivery to the eye
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2012111029A3 (fr) * 2011-02-18 2012-10-18 M/S. Appasamy Associates Composition ophtalmique pour la dilatation des pupilles
EP2675455A2 (fr) * 2011-02-18 2013-12-25 M/S. Appasamy Associates Composition ophtalmique pour la dilatation des pupilles
EP2675455A4 (fr) * 2011-02-18 2014-07-16 M S Appasamy Associates Composition ophtalmique pour la dilatation des pupilles
US9066856B2 (en) 2012-10-24 2015-06-30 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9486406B2 (en) 2012-10-24 2016-11-08 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9855246B2 (en) 2012-10-24 2018-01-02 Omeros Corporation Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Also Published As

Publication number Publication date
EP1858481B1 (fr) 2019-05-08
LT1858481T (lt) 2019-07-10
FR2882930B1 (fr) 2009-03-27
HRP20191044T1 (hr) 2019-09-06
LTPA2019017I1 (lt) 2019-12-10
CA2598503C (fr) 2014-01-28
NL301017I2 (nl) 2020-04-30
WO2006095095A1 (fr) 2006-09-14
US20120220637A1 (en) 2012-08-30
PL1858481T3 (pl) 2019-09-30
NO20074850L (no) 2007-09-24
NO2017008I2 (no) 2017-03-24
TR201908487T4 (tr) 2019-07-22
JP2008532985A (ja) 2008-08-21
LUC00136I2 (fr) 2021-02-12
CN101151018A (zh) 2008-03-26
CA2598503A1 (fr) 2006-09-14
LUC00136I1 (fr) 2019-11-04
NL301017I1 (nl) 2019-11-06
CY2019042I2 (el) 2020-05-29
FR2882930A1 (fr) 2006-09-15
NO2017008I1 (no) 2017-03-24
CY1121865T1 (el) 2020-05-29
TNSN07343A1 (fr) 2008-12-31
ES2728071T3 (es) 2019-10-22
KR20070111501A (ko) 2007-11-21
MA29269B1 (fr) 2008-02-01
MX2007010295A (es) 2007-12-11
US9289399B2 (en) 2016-03-22
SI1858481T1 (sl) 2019-08-30
NO339793B1 (no) 2017-01-30
HUE043668T2 (hu) 2019-08-28
IL185197A0 (en) 2008-01-06
BRPI0607416A2 (pt) 2009-09-08
EP1858481A1 (fr) 2007-11-28
RU2007137115A (ru) 2009-04-20
PT1858481T (pt) 2019-06-14
CY2019042I1 (el) 2020-05-29
DK1858481T3 (da) 2019-06-03
RU2392925C2 (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
US9289399B2 (en) Ophthalmologic compositions and use mode thereof
CA2423354C (fr) Preparations et medications nasales, inhalables et ophtalmiques locales a conservation spontanee
US20230355551A1 (en) Stabilization of epinephrine formulations
JP5736635B2 (ja) ドライアイ治療剤
US11925608B2 (en) Stabilization of epinephrine formulations
AU2017315757A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
EP3445331B1 (fr) Compositions ophtalmiques pharmaceutiques sans conservateur
US20050080043A1 (en) Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP1283043B1 (fr) Composition ophtalmique
US20160089375A1 (en) Topical ocular analgesic agents
US20210346318A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JPS588013A (ja) 緑内障および高眼圧症の治療用薬学的調合物
WO2018144786A1 (fr) Solution antibiotique et méthode d'injection pour prévenir des infections ophtalmiques
JPH0256422A (ja) 静脈性血栓症の予防または軽減用組成物
BRPI0607416B1 (pt) Composição farmacêutica para administração intracameral compreendendo uma combinação de agentes parasimpatolítico, simpatomimético e anestésico local, e uso da mesma na preparação de medicamento
Potter et al. Ocular and cardiac β-antagonism by timolol prodrugs, timolol and levobunolol
JPH0383931A (ja) 低刺激性ｇｒｆ経鼻投与製剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABORATOIRES THEA, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHATIB, WALID;REEL/FRAME:019801/0767

Effective date: 20070723

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION